Skip to main content
Clinical Trials/NCT04831879
NCT04831879
Unknown
Not Applicable

Automated Mechanical Peripheral Stimulation to Treat Freezing of Gait in Patients With Parkinson's Disease and Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) - a Randomized Double-blind, Sham Controlled, Cross-over Trial

Gondola Medical Technologies SA1 site in 1 country40 target enrollmentMarch 25, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Gondola Medical Technologies SA
Enrollment
40
Locations
1
Primary Endpoint
Freezing of gait assessment course
Last Updated
5 years ago

Overview

Brief Summary

The objective is to investigate whether AMPS (Automated Mechanical Peripheral Stimulation) is effective in reduction of FOG measured via the FOG-AC (Freezing Of Gait Assessment Course) in people with Parkinson Disease and STN-DBS (Subthalamic Nucleus Deep Brain Stimulation) in a randomized, double-blind, sham-controlled, cross-over trial

Detailed Description

The effects of AMPS treatment (effective vs sham) will be measured using the FOG-AC assessment. Patients will be randomized to receive either AMPS treatment and then sham or sham and then AMPS. Each treatment phase will be 4 weeks of treatment, separated by a 6-week washout period.

Registry
clinicaltrials.gov
Start Date
March 25, 2021
End Date
June 30, 2022
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Gondola Medical Technologies SA
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Informed Consent as documented by signature (Appendix Informed Consent Form)
  • ≥18 years old
  • Diagnosis of Parkinson's Disease according to the United Kingdom Brain Bank Criteria
  • Bilateral STN-DBS for at least 6 months
  • Moderate to severe FOG i.e. FOG-AC ≥8 pts.

Exclusion Criteria

  • Known or suspected non-compliance, drug or alcohol abuse,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc. of the participant,
  • Participation in another study with investigational drug within the 30 days preceding and during the present study,
  • Previous enrolment into the current study,
  • Pregnancy
  • Enrolment of the investigator, his/her family members, employees and other dependent persons,
  • L-Dopa induced-freezing (defined by medical history),
  • DBS-induced freezing (defined by medical history),
  • Clinically relevant depression
  • Clinically relevant cognitive impairments

Outcomes

Primary Outcomes

Freezing of gait assessment course

Time Frame: 4 weeks

The primary outcome is the change in FOG severity measured by the freezing of gait assessment course (FOG-AC) and evaluated by a blinded observer using video recordings (difference between the change after 4 weeks of effective AMPS treatment and after 4 weeks of sham-treatment). Min: 0 Max: 36 Higher score indicates worse symptoms.

Secondary Outcomes

  • Freezing of Gait Questionnaire(4 weeks)
  • Movement Disorder Society - Unified Parkinson's Disease Rating Scale part I-IV(4 weeks)
  • Parkinson's Disease Questionnaire(4 weeks)
  • Clinical Global Impression Severity and Improvement Scores(4 weeks)
  • Timed up and go test(4 weeks)
  • Falls Efficacy Scale - International(4 weeks)
  • Fast 360° turns(4 weeks)
  • 30-meter walk(4 weeks)

Study Sites (1)

Loading locations...

Similar Trials